Rare Disease Patients: Placebo Controls, Sham Surgeries Not Appropriate For Gene Therapy Trials
Executive Summary
Advocates also worry that long follow-up times could prevent participation in future clinical trials.
You may also be interested in...
Neonatal Drug Development Could Benefit From Rare Disease Experience
Early parent involvement in drug development and clinical trial design could improve recruitment and outcomes, stakeholders argue.
Y-mAbs’ I-Omburtamab Offers Another Example Of The Limits To US FDA’s Regulatory Flexibility
Even in a rare disease with no approved treatments, the agency shows once again that without clear efficacy data, FDA has few options for approval.
New Name, Old Problems: US FDA’s Cell And Gene Therapy Office Still Facing Growth Challenges
The group will be called the Office of Therapeutic Products, but needs more people to handle its increasing workload.